Making a big move into the vaccine business, the Swiss pharmaceutical giant Novartis said on Monday that it would acquire control of the Chiron Corp, a manufacturer of flu shots that has been beset by quality control problems.
Novartis, which already owns 42 percent of Chiron, will pay US$45 a share, or a total of US$5.1 billion, for the 113 million shares of Chiron it does not already own.
The price, which has been approved by the Chiron directors who are not affiliated with Novartis, is US$5 a share higher than a previous offer those directors rejected as inadequate.
The acquisition will mean the end of Chiron, founded in 1981. The firm is one of the oldest and most successful US biotechnology companies.
The acquisition is the latest sign that pharmaceutical companies are seeing a new attractiveness in the vaccine business, which has often been characterized as offering low profits and slow growth.
The new interest stems in part from the fear of a flu pandemic. Some newer vaccines also sell for higher prices than vaccines in the past.
Vaccines are an "attractive new growth platform" for Novartis, the company's chief executive, Daniel Vasella, told securities analysts.
"We see that there are innovative targets which can be attacked," he added. "We see innovative new technologies."
Recently, GlaxoSmithKline, which has long been in the vaccine business, offered to buy ID Biomedical, a Canadian manufacturer of flu shots.
Vasella vowed to turn around Chiron's vaccine business. Chiron's factory in Liverpool was closed last year by British regulators because of sanitary problems, causing a big flu shot shortage in the US last winter. This year, the Liverpool factory is operating at reduced capacity, but another Chiron flu vaccine factory in Germany has been closed because of contamination.
In addition to vaccines, Chiron sells some drugs and has a fast-growing business for tests of donated blood for viruses like HIV and hepatitis C.
The acquisition is subject to the approval of a majority of Chiron's shareholders.
Novartis executives said the company was confident the transaction would be cleared by regulators in the US and Europe and close in the first half of next year.
One potential antitrust issue is that Novartis owns about 30 percent of Roche Holding, Chiron's main rival in blood testing. But Novartis is likely to argue that it has no control over Roche's business.
Another issue, said Geoffrey Porges, an analyst at Sanford C. Bernstein & Co, is that Chiron is the only major US manufacturer of flu vaccines and it would become foreign-owned.
US federal officials have been pushing for a domestic supply of flu vaccines and drugs because in a pandemic, governments could nationalize manufacturers or ban exports in order to protect their own populations.
Washington pushed Roche, for example, to make its antiflu drug Tamiflu in the US. The risk of relying on foreign manufacturers was highlighted last year when the British government's shutdown of Chiron's factory caught the US by surprise.
Still, while Chiron is American, its flu vaccine factories, which it acquired from other companies, are in Europe. The lone US flu vaccine factory, in Swiftwater, Pennsylvania, is owned by a French company, Sanofi-Aventis.
Novartis is likely to make the case that with its greater resources, it would be a more reliable supplier to the US than Chiron.
In addition, Vasella said Novartis would consider building a flu vaccine factory in the US if the government made it attractive enough.
Chiron, which had revenue of US$1.7 billion and income from continuing operations of US$60 million last year, is perhaps best known for discovering the virus that causes hepatitis C. But it has been far less successful at developing drugs than some other early biotechnology companies like Genentech and Amgen.
Ciba-Geigy, which later merged with Sandoz to form Novartis, acquired its stake in Chiron about 10 years ago. Novartis's business never benefited from that relationship, in contrast to Roche, which has obtained many of its best-selling drugs from its investment in Genentech.
Novartis said it hoped to achieve US$200 million in cost savings from the merger. It did not say whether there would be layoffs.
RETHINK? The defense ministry and Navy Command Headquarters could take over the indigenous submarine project and change its production timeline, a source said Admiral Huang Shu-kuang’s (黃曙光) resignation as head of the Indigenous Submarine Program and as a member of the National Security Council could affect the production of submarines, a source said yesterday. Huang in a statement last night said he had decided to resign due to national security concerns while expressing the hope that it would put a stop to political wrangling that only undermines the advancement of the nation’s defense capabilities. Taiwan People’s Party Legislator Vivian Huang (黃珊珊) yesterday said that the admiral, her older brother, felt it was time for him to step down and that he had completed what he
Taiwan has experienced its most significant improvement in the QS World University Rankings by Subject, data provided on Sunday by international higher education analyst Quacquarelli Symonds (QS) showed. Compared with last year’s edition of the rankings, which measure academic excellence and influence, Taiwanese universities made great improvements in the H Index metric, which evaluates research productivity and its impact, with a notable 30 percent increase overall, QS said. Taiwanese universities also made notable progress in the Citations per Paper metric, which measures the impact of research, achieving a 13 percent increase. Taiwanese universities gained 10 percent in Academic Reputation, but declined 18 percent
CHINA REACTS: The patrol and reconnaissance plane ‘transited the Taiwan Strait in international airspace,’ the 7th Fleet said, while Taipei said it saw nothing unusual The US 7th Fleet yesterday said that a US Navy P-8A Poseidon flew through the Taiwan Strait, a day after US and Chinese defense heads held their first talks since November 2022 in an effort to reduce regional tensions. The patrol and reconnaissance plane “transited the Taiwan Strait in international airspace,” the 7th Fleet said in a news release. “By operating within the Taiwan Strait in accordance with international law, the United States upholds the navigational rights and freedoms of all nations.” In a separate statement, the Ministry of National Defense said that it monitored nearby waters and airspace as the aircraft
UNDER DISCUSSION: The combatant command would integrate fast attack boat and anti-ship missile groups to defend waters closest to the coastline, a source said The military could establish a new combatant command as early as 2026, which would be tasked with defending Taiwan’s territorial waters 24 nautical miles (44.4km) from the nation’s coastline, a source familiar with the matter said yesterday. The new command, which would fall under the Naval Command Headquarters, would be led by a vice admiral and integrate existing fast attack boat and anti-ship missile groups, along with the Naval Maritime Surveillance and Reconnaissance Command, said the source, who asked to remain anonymous. It could be launched by 2026, but details are being discussed and no final timetable has been announced, the source